Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in Moderate to Severe Hidradenitis Suppurativa
NCT03512275Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in hidradenitis suppurativa (HS), sponsored by Janssen Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03512275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512275.